Search
Search
Joseph J. Allen, OD, FAAO, Dipl ABO
Show Description +
Joseph J. Allen, OD, FAAO, Dipl ABO, spends this episode of Eye Care Insiders discussing phentolamine ophthalmic solution 0.75% (Ryzumvi, Ocuphire Pharma), explaining how it works, reviewing clinical trial findings, potential adverse events, how it could fit into your clinic, and more.
Posted: 10/31/2023
Joseph J. Allen, OD, FAAO, Dipl ABO
Joseph J. Allen, OD, FAAO, Dipl ABO, spends this episode of Eye Care Insiders discussing phentolamine ophthalmic solution 0.75% (Ryzumvi, Ocuphire Pharma), explaining how it works, reviewing clinical trial findings, potential adverse events, how it could fit into your clinic, and more.
Posted: 10/31/2023
.mp4.00_05_41_04.Still001_1680887186.jpg?auto=compress,format&w=180)
.00_13_09_19.Still001_1676069079.jpg?auto=compress,format&w=180)
_1701789080.png?auto=compress,format&w=180)
Please log in to leave a comment.
Comments
Just Now
Anonymous
1 year ago
Can you do an update on Ryzumvi?
Kerry Givens
1 year ago
The main issue with RevEyes was cost. We spent several thousand bucks a year on the product. My ophthalmology practice absorbed the expense since we didn't feel right billing the patient to undo a situation that we created. Frankly patients LOVED RevEyes even though it was not exactly magical---- basically it shaved a couple of hours off the back-end of their dilation, which was not helpful for their drive home. As best I could tell, we were the only practice in our town that used RevEyes, which I suspect was a reflection on its high cost. Patients still ask for it, many years after it was inexplicably taken off the market.
Somer Lyons
1 year ago
I will use it the first minute it is available! I miss RevEyes!